University of Pittsburgh Health Sciences eLearning Environment Internet-based Studies in Education and Research
Step by Step
INTRODUCTION
10/18/2016 - Medical Grand Rounds: Gene Therapy for Sickle Cell Disease: Scientific Fact or Science Fiction?
QUIZ
EVALUATION
CERTIFICATE
INTRODUCTION
Credit Hours: CME 1.00
Target Audience:
Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.
Educational Objectives:
Upon completion of this activity, participants should be able to:
- Increase patient treatment options with gene therapy.
- Improve patient education with gene therapy information.
- Improve diagnostic skills for recognizing high risk sickle cell disease.
Suggested Additional Reading:
- Goodman MA, Malik P. The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challenges. Ther Adv Hematol. 2016 Oct;7(5):302-315. Review. PubMed PMID: 27695619.
- The Lancet Haematology. Gene therapy for sickle cell disease. Lancet Haematol. 2016 Oct;3(10):e446. doi: 10.1016/S2352-3026(16)30130-2. PubMed PMID: 27692301.
- Traxler EA, Yao Y, Wang YD, Woodard KJ, Kurita R, Nakamura Y, Hughes JR, Hardison RC, Blobel GA, Li C, Weiss MJ. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition. Nat Med. 2016 Sep;22(9):987-90. doi: 10.1038/nm.4170. Epub 2016 Aug 15. PubMed PMID: 27525524.
Authors:
Brett Kaufman, PhD
—
Associate Professor of Medicine
Division of Cardiology
No relationships with industry relevant to the content of this educational activity have been disclosed.
No relationships with industry relevant to the content of this educational activity have been disclosed.
Greg Kato, MD
—
Professor of Medicine
Division of Hematology/Oncology
Director, Sickle Cell Center of Excellence
Dr. Kato receives Grant/Research support from Bayer AG. He is a consultant for Mast Therapeutics.
Dr. Kato receives Grant/Research support from Bayer AG. He is a consultant for Mast Therapeutics.
No other members of the planning committee, speakers, presenters,
authors, content reviewers and/or anyone else in a position to
control the content of this education activity have relevant
financial relationships with any companies whose primary business
is producing, marketing, selling, re-selling, or distributing
healthcare products used by or on patients.
This activity is approved for AMA PRA Category 1 Creditâ„¢
The University of Pittsburgh is an affirmative action, equal opportunity institution.